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Background: The randomized phase of the PARTNER trial was an early transcatheter aortic valve replacement (TAVR) experience for US sites and 
operators using the Edwards Sapien valve. Subsequently, 1080 patients were treated via transfemoral (TF) approach as part of a non-randomized 
continued access (NRCA) registry.
methods: Inclusion/exclusion criteria, data collection and monitoring were the same in NRCA as in the randomized controlled trial (RCT); core labs 
for data analysis remained unchanged. Baseline characteristics and outcomes of the 423 patients who underwent TF-TAVR in the RCT were compared 
to the 1080 patients who underwent TF TAVR in the NRCA phase. Event rates are presented as Kaplan-Meier estimates.
results: NRCA patients were older (mean age 84.8 ± 7.8 vs 83.6 ± 7.6, p< 0.001), but had fewer comorbidities as evidenced by a lower mean 
STS score (10.9 ± 3.8 vs 11.5 ± 4.5, p<0.001) and lower frequency of cerebrovascular disease (21.4 vs 26.1, p=0.06), peripheral vascular disease 
(27.4 vs 33.3, p=0.02) and renal disease (15.0 vs 20.4, p=0.01). In hospital mortality was similar (4.9% vs 5.7%, p=0.54); however, strokes were 
less frequent in NRCA than RCT (3.3% vs 5.4%, p=0.06). Other complications including vascular and bleeding events in the NRCA population are still 
undergoing adjudication, and will be available for presentation. Procedure times were shorter and rates of post-dilatation were lower (p<0.0001 for 
both measures), suggesting a learning curve. One-year mortality (18.0% vs 25.8%, p=0.001) and strokes (4.8% vs 7.3%, p=0.05) were lower in NRCA. 
The frequency of mod-severe paravalvular regurgitation (PAR) was not different between RCT and NRCA (15.3% vs 14.9%) and mod- severe PAR was 
associated with higher late mortality compared to mild or none-trace PAR (37.8% vs 21.7% vs 20.2%, p<0.001).
conclusions: The favorable results after TF-TAVR achieved in the PARTNER RCT were reproduced in the subsequent NRCA. Procedural outcomes 
have improved with device iteration and procedural learning. The improvement in long term results suggests better patient selection with greater 
experience. PAR remains a concern with current generation devices. 
